-$0.60 Earnings Per Share Expected for Zymeworks Inc (NYSE:ZYME) This Quarter

Share on StockTwits

Brokerages predict that Zymeworks Inc (NYSE:ZYME) will report ($0.60) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Zymeworks’ earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.69). Zymeworks posted earnings per share of ($0.59) in the same quarter last year, which would suggest a negative year over year growth rate of 1.7%. The business is expected to announce its next earnings report on Tuesday, November 5th.

On average, analysts expect that Zymeworks will report full-year earnings of ($2.44) per share for the current year, with EPS estimates ranging from ($2.92) to ($1.95). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.81) per share, with EPS estimates ranging from ($3.51) to ($1.68). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Zymeworks.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.06). The firm had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $7.25 million. Zymeworks had a negative net margin of 102.78% and a negative return on equity of 24.44%.

ZYME has been the subject of a number of research reports. ValuEngine lowered Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, May 18th. Wells Fargo & Co boosted their price target on Zymeworks from $37.00 to $42.00 and gave the company an “outperform” rating in a report on Monday, April 22nd. Barclays boosted their price target on Zymeworks from $15.00 to $23.00 and gave the company an “equal weight” rating in a report on Monday, August 5th. Raymond James set a $36.00 price target on Zymeworks and gave the company an “outperform” rating in a report on Wednesday, August 7th. Finally, Deutsche Bank initiated coverage on Zymeworks in a report on Thursday, July 18th. They issued a “buy” rating and a $34.00 price target for the company. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Zymeworks presently has an average rating of “Buy” and an average target price of $30.67.

Shares of NYSE ZYME traded up $1.39 during trading hours on Tuesday, reaching $26.39. The stock had a trading volume of 373,700 shares, compared to its average volume of 150,028. The company has a current ratio of 9.07, a quick ratio of 9.07 and a debt-to-equity ratio of 0.02. The firm has a market cap of $979.44 million, a price-to-earnings ratio of -20.94 and a beta of 1.47. The business’s fifty day moving average price is $23.80 and its two-hundred day moving average price is $18.81. Zymeworks has a 52-week low of $10.72 and a 52-week high of $27.16.

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Zymeworks by 42.3% during the second quarter. BlackRock Inc. now owns 1,679 shares of the company’s stock worth $37,000 after buying an additional 499 shares during the period. Advisor Group Inc. lifted its holdings in Zymeworks by 42.7% during the second quarter. Advisor Group Inc. now owns 1,806 shares of the company’s stock worth $40,000 after buying an additional 540 shares during the period. Bank of Montreal Can lifted its holdings in Zymeworks by 36.1% during the first quarter. Bank of Montreal Can now owns 5,960 shares of the company’s stock worth $96,000 after buying an additional 1,580 shares during the period. A.R.T. Advisors LLC purchased a new stake in Zymeworks during the second quarter worth $201,000. Finally, Jane Street Group LLC purchased a new stake in Zymeworks during the second quarter worth $211,000. Institutional investors own 30.43% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

Recommended Story: What is a growth and income fund?

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.